Affiliation:
1. Novartis Pharmaceuticals Corporation , East Hanover, New Jersey , USA
2. Novartis Pharma AG , Basel , Switzerland
Abstract
Abstract
Recurrent events are often important endpoints in randomized clinical trials. For example, the number of recurrent disease-related hospitalizations may be considered as a clinically meaningful endpoint in cardiovascular studies. In some settings, the recurrent event process may be terminated by an event such as death, which makes it more challenging to define and estimate a causal treatment effect on recurrent event endpoints. In this paper, we focus on the principal stratum estimand, where the treatment effect of interest on recurrent events is defined among subjects who would be alive regardless of the assigned treatment. For the estimation of the principal stratum effect in randomized clinical trials, we propose a Bayesian approach based on a joint model of the recurrent event and death processes with a frailty term accounting for within-subject correlation. We also present Bayesian posterior predictive check procedures for assessing the model fit. The proposed approaches are demonstrated in the randomized Phase III chronic heart failure trial PARAGON-HF (NCT01920711).
Publisher
Oxford University Press (OUP)
Subject
Applied Mathematics,General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,Statistics and Probability
Reference41 articles.
1. Estimands and their role in clinical trials;Akacha;Statistics in Biopharmaceutical Research,2017
2. A tutorial on frailty models;Balan;Statistical Methods in Medical Research,2020
3. Estimating the treatment effect in a subgroup defined by an early post-baseline biomarker measurement in randomized clinical trials with time-to-event endpoint;Bornkamp;Statistics in Biopharmaceutical Research,2020
4. Principal stratum strategy: potential role in drug development;Bornkamp;Pharmaceutical Statistics,2021
5. Reporting of lost to follow-up and treatment discontinuation in pharmacotherapy and device trials in chronic heart failure: a systematic review;Campbell;Circulation: Heart Failure,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献